Today's five.

Meta agreed to a $17 billion settlement with 47 states over allegations that Facebook and Instagram were deliberately designed to addict children — and that Meta knew, and didn't say anything. The deal includes a two-hour daily screen limit for teens, stricter age verification, and funding for youth mental health programs. Axios compared it directly to the 1990s tobacco settlement; the Chicago Sun-Times noted Zuckerberg was expected to testify before the trial got cut short. Meta is now calling on every other platform to sign on too, which is either genuine industry leadership or a very clever way to share the legal exposure.

Dolly Parton died at 80, and the tributes are instructive in what they can't agree on. BBC covered the fashion. Slate covered the myth-making. The LA Times covered her advocacy for undocumented immigrants. Reason covered her politics-defying favorability numbers. Vox called her America's last unifying celebrity. The remarkable thing isn't that everyone loved her — it's that everyone loved her for completely different reasons, and she somehow earned all of them. She donated to COVID vaccine research, built a literacy empire, and still had time for the rhinestones. Dolly Parton wasn't a symbol people projected onto. She was just, apparently, actually like that.

The White House posted a bald eagle attacking a Canada goose on social media, which is one way to conduct foreign policy. After trade talks collapsed, Trump imposed 50% tariffs on roughly $20 billion of Canadian imports. Canada is retaliating dollar for dollar starting September 8 — steel, aluminum, dairy, electronics. Trump is threatening another escalation on January 1 targeting cars and auto parts. NPR focused on Michigan's $23 billion cross-border exposure. The Times buried the real punchline: the only country clearly winning this is China. The two largest trading partners on earth are doing this to each other.

For about fifty years, the protein that drives 90% of pancreatic cancer cases was considered undruggable — too flat, no obvious place to attach anything. Revolution Medicines found a pocket. Daraxonrasib, approved Wednesday under the brand name Rasonque, nearly doubled survival time in trials: 13.2 months versus 6.6 on chemotherapy, with fewer severe side effects. The FDA fast-tracked it. The Wall Street Journal got an oncologist to say "this is life-altering" on record, which oncologists do not do lightly. One pharma analytics firm projects over $20 billion in annual sales, which tells you how many people this disease touches.

Two people died in a helicopter crash in Kenya, and someone in Florida apparently saw an opportunity. Burglars — one man, one woman, per prosecutors — targeted the Coral Gables home of the deceased couple almost immediately after news of their deaths broke, making off with roughly $500,000 in property, including a Range Rover and a Porsche Taycan. The Daily Mail went heavy on moral outrage; Miami New Times kept it procedural. The mechanics of what happened are the same either way: someone was monitoring the news specifically to identify empty houses. That's not opportunistic. That's a system.